These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29624457)

  • 1. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.
    Ellsworth JL; O'Callaghan M; Rubin H; Seymour A
    Hum Gene Ther Clin Dev; 2018 Mar; 29(1):60-67. PubMed ID: 29624457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.
    Calcedo R; Wilson JM
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):79-82. PubMed ID: 27314914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors.
    Navarro-Oliveros M; Vidaurrazaga A; Soares Guerra G; Castellana D; Embade N; Millet O; Marigorta UM; Abrescia NGA
    Sci Rep; 2024 Jul; 14(1):15941. PubMed ID: 38987633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.
    Rapti K; Louis-Jeune V; Kohlbrenner E; Ishikawa K; Ladage D; Zolotukhin S; Hajjar RJ; Weber T
    Mol Ther; 2012 Jan; 20(1):73-83. PubMed ID: 21915102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States.
    Khatri A; Shelke R; Guan S; Somanathan S
    Hum Gene Ther; 2022 Apr; 33(7-8):442-450. PubMed ID: 34861783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of adeno-associated virus neutralizing antibody activity for clinical application.
    Wang M; Crosby A; Hastie E; Samulski JJ; McPhee S; Joshua G; Samulski RJ; Li C
    Gene Ther; 2015 Dec; 22(12):984-92. PubMed ID: 26125606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
    Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
    J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart.
    Li X; La Salvia S; Liang Y; Adamiak M; Kohlbrenner E; Jeong D; Chepurko E; Ceholski D; Lopez-Gordo E; Yoon S; Mathiyalagan P; Agarwal N; Jha D; Lodha S; Daaboul G; Phan A; Raisinghani N; Zhang S; Zangi L; Gonzalez-Kozlova E; Dubois N; Dogra N; Hajjar RJ; Sahoo S
    Circulation; 2023 Aug; 148(5):405-425. PubMed ID: 37409482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexisting Neutralizing Antibodies against Different Adeno-Associated Virus Serotypes in Humans and Large Animal Models for Gene Therapy.
    Ail D; Dalkara D
    Adv Exp Med Biol; 2023; 1415():117-123. PubMed ID: 37440023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.